Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

Rhea-AI Summary

On June 8, 2022, Terns Pharmaceuticals (Nasdaq: TERN) announced that five abstracts concerning its non-alcoholic steatohepatitis (NASH) programs have been accepted for presentation at The International Liver Congress 2022, scheduled for June 22-26 in London. Key presentations include results from a first-in-human trial of TERN-501 and safety data on TERN-101 and TERN-201, showcasing their potential efficacy and favorable safety profiles. All abstracts will be published in the Journal of Hepatology.

Positive

• Five abstracts accepted for presentation at The International Liver Congress 2022.
• Positive clinical data reported for TERN-501 in a first-in-human trial.
• Favorable safety and efficacy outcomes demonstrated for TERN-101 and TERN-201.

Negative

• None.

FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis (NASH) programs within the Company's portfolio were accepted for presentation at The International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom. The abstracts were published in the July supplement of the Journal of Hepatology.

Details of the Terns presentations at The International Liver Congress 2022 are as follows:

Oral Presentation
Title: Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study
Publication Number: OS123
Presenter: Cara Nelson
Date and Time: Saturday, June 25 6:15 p.m. BT

Poster Presentations
Title: Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study
Publication Number: SAT107
Presenter: Kris Kowdley

Title: Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients
Publication Number: SAT108
Presenter: Cara Nelson

Title: TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
Publication Number: SAT106
Presenter: Kris Kowdley

Title: Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study
Publication Number: SAT142
Presenter: Mazen Noureddin

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH, obesity and cancer. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com 

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com 

FAQ

What were the key findings of Terns Pharmaceuticals presented at The International Liver Congress 2022?

Terns Pharmaceuticals presented five abstracts detailing positive clinical data for its NASH programs, emphasizing the safety and efficacy of TERN-501, TERN-101, and TERN-201.

What is the significance of TERN-501's presentation at the International Liver Congress?

The presentation of TERN-501 underscores its well-tolerated profile and significant dose-dependent changes in serum lipids from the first-in-human study.

When will the abstracts regarding Terns Pharmaceuticals be published?

The abstracts will be published in the July supplement of the Journal of Hepatology.

What are the implications of the data presented by Terns Pharmaceuticals on its NASH programs?

The positive data from the clinical studies may enhance investor confidence and support the ongoing development of Terns' therapies for non-alcoholic steatohepatitis.